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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORPlatelet Reactivity Is Preferred
Over Genotyping in Monitoring
Efﬁcacy of Antiplatelet Therapy
We read with great interest the report by Viviani Anselmi et al. (1)
on the predictability of platelet reactivity as compared with gene
polymorphism in patients undergoing elective percutaneous coro-
nary intervention (PCI). The authors conclude that CYP2C19
metabolizer status independently predicts major adverse cardiac
events, whereas platelet reactivity is only an independent predictor
in high-risk patients.
Notwithstanding the well-performed and large study (1), we
are puzzled by these results. Because the underlying hypothesis
of the present study is that an inferior response to thienopyr-
idines is associated with (recurrent) ischemic events, the question
is whether genotyping or phenotyping is preferred in identifying
patients at risk. Phenotyping (platelet reactivity as assessed by
the VerifyNow cartridge [Accumetrics, San Diego, California])
has been explored in a large number of observational studies as
well as in the pharmacodynamics analyses of several randomized
clinical trials. In contrast to the ﬁndings of the present study, the
bulk of these data support the supposition that among patients
undergoing PCI treated with clopidogrel or prasugrel, higher
values of platelet reactivity units are associated with ischemic
events (2,3). In addition, platelet reactivity as assessed by the
VerifyNow test is correlated with the active metabolite of clo-
pidogrel (4). Furthermore, in the POPular (Do Platelet Function
Assays Predict Clinical Outcomes in clopidogrel pretreated pa-
tients undergoing elective PCI) (the POPular Study) (2), a sig-
niﬁcant correlation between (high) on-treatment platelet reactivity
and CYP2C19 metabolizer status has been established (5). This is
in line with a large meta-analysis on CYP2C19 genotyping and
outcome in clopidogrel-treated patients, which demonstrated an
association between CYP2C19 genotype and on-treatment platelet
reactivity but lacked proof of a signiﬁcant association of genotype
with cardiovascular events (6). An argument in favor of genotyping
is that it is stable over time, whereas platelet reactivity is not,
because it is inﬂuenced by multiple clinical determinants as well as
laboratory parameters and comedication (7). As a result of variable
baseline platelet reactivity, a response that is stable over time and
equal among individuals can result in a broad range of on-treatment
platelet reactivity levels (8). Therefore, we consider monitoring
platelet reactivity a more appropriate approach of monitoring anti-
platelet therapy.
The results of the current study point precisely in the opposite
direction, and we are curious how the authors explain these dif-
ferences and what their ﬁndings imply for daily clinical practice.
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Reply
Platelet Reactivity Is Preferred Over Genotyping
in Monitoring Efﬁcacy of Antiplatelet Therapy
We thank Drs. Breet and ten Berg for their interest in our paper
(1). When we designed our study, we aimed to conﬁrm and expand
previous observations demonstrating the clinical usefulness of clo-
pidogrel-pathway genotyping and on-treatment platelet residual
(OTR) testing in predicting major adverse cardiac events (MACE)
in patients with stable coronary artery disease (CAD) receiving
drug-eluting stents (DES) and under dual antiplatelet (clopidogrel
plus aspirin) therapy. Our results conﬁrmed that CYP2C19
metabolizer status is an independent predictor of MACE after
DES implantation and can be used for prognostication in all stable
CAD patients. In contrast, high OTR, as assessed with the
